OtherImaging, Diagnosis, Prognosis
Topoisomerase IIα Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma
Ipatia A. Doussis-Anagnostopoulou, Theodoros P. Vassilakopoulos, Irini Thymara, Penelope Korkolopoulou, Maria K. Angelopoulou, Marina P. Siakantaris, Styliani I. Kokoris, Evangelia M. Dimitriadou, Christina Kalpadakis, Marina Matzouranis, Loukas Kaklamanis, Panayiotis Panayiotidis, Marie-Christine Kyrtsonis, Athina Androulaki, Efstratios Patsouris, Christos Kittas, Gerassimos A. Pangalis
DOI: 10.1158/1078-0432.CCR-07-1395 Published 15 March 2008
Ipatia A. Doussis-Anagnostopoulou
Theodoros P. Vassilakopoulos
Irini Thymara
Penelope Korkolopoulou
Maria K. Angelopoulou
Marina P. Siakantaris
Styliani I. Kokoris
Evangelia M. Dimitriadou
Christina Kalpadakis
Marina Matzouranis
Loukas Kaklamanis
Panayiotis Panayiotidis
Marie-Christine Kyrtsonis
Athina Androulaki
Efstratios Patsouris
Christos Kittas
Fig. 1.
Fig. 1.
A, topoisomerase IIα expression was seen in all cases and was mainly present in the neoplastic HRS cells and variants, as a diffuse nuclear staining. B, C, D, effect of topoisomerase IIα expression on the outcome of patients with Hodgkin's lymphoma treated with ABVD or equivalent regimens with or without radiotherapy: (B) Failure Free Survival (FFS) in all patients; (C) FFS in early clinical stages (IA and IIA); (D) FFS in advanced clinical stages (IB, IIB, III and IV).
April 2021
Volume 27, Issue 8
Volume 27, Issue 8
Fig. 1.
Clin Cancer Res Dec 1969 ;